Mir Basharath Alikhan, MD
Director, Molecular Oncology; Program Director, Molecular Genetic Pathology Fellowship; Hematopathologist, NorthShore University Health System; Clinical Assistant Professor, Pritzker School of Medicine, University of Chicago
Mir Basharath Alikhan, MD
Director, Molecular Oncology; Program Director, Molecular Genetic Pathology Fellowship; Hematopathologist, NorthShore University Health System; Clinical Assistant Professor, Pritzker School of Medicine, University of Chicago
Mir B. Alikhan, MD is the Director of molecular oncology at NorthShore University HealthSystem in Evanston, IL. He oversees the daily operations of the Molecular Diagnostics lab as it pertains to molecular testing of cancer patients. This encompasses multiple next-generation sequencing assays for both solid tumors and hematopoietic neoplasms. He also has a passion for teaching, with award-winning service as a teacher for pathology residents, lab technologists, and medical students in both molecular diagnostics as well as hematopathology. He also serves as program director for the Molecular Genetic Pathology Fellowship, which is offered jointly with the University of Chicago.
In addition to teaching, he has spoken at numerous local and national forums regarding the utility of next-generation sequencing, particularly in the field of hematopathology. He also serves as Associate Editor of the American Society of Hematology’s Image Bank, an online resource for curated images and succinct descriptions of both common and unusual hematopoietic diseases. He also serves as a hematopathologist, focusing on the diagnosis and management of patients with leukemias and lymphomas.
Marilyn M. Bui, MD, PhD
Scientific Director, Analytic Microscopy Core; Section Head, Bone & Soft Tissue Pathology, Moffitt Cancer Center; Professor & Program Director, Cytopathology, University of South Florida Morsani College of Medicine
Marilyn M. Bui, MD, PhD
Scientific Director, Analytic Microscopy Core; Section Head, Bone & Soft Tissue Pathology, Moffitt Cancer Center; Professor & Program Director, Cytopathology, University of South Florida Morsani College of Medicine
Marilyn M. Bui, MD, PhD is a Senior Member and Professor of Pathology in the Department of Pathology at Moffitt Cancer Center in Tampa, FL. Her mission is to deliver the best possible patient care by combining her expertise in bone and soft tissue pathology, cytopathology, biomarker testing, and digital pathology/AI. In addition to providing excellent patient care and received the 2019 College of American Pathologists (CAP) Distinguished Patient Care Award, she is an award-winning educator/mentor, researcher, and a pathology leader. Being an inventor, she has received 3 patents in digital pathology and cancer diagnostics. As a translational researcher, she is the study pathologist for multiple research grants and has published over 200 articles, 24 book chapters and 3 books. She has frequently lectured both nationally and internationally, including keynote presentations. She is the editorial board member of multiple journals. As a pathology leader, she served as the President of the Digital Pathology Association (2019) and the President of Medical Staff of Moffitt (2018-2020). She had chaired multiple committees of the CAP and currently chairs the digital and computational pathology committee.
Matthew Goldberg, MD
Medical Director, Castle Biosciences; Assistant Clinical Professor, Dermatology, Icahn School of Medicine, Mount Sinai, New York City
Matthew Goldberg, MD
Medical Director, Castle Biosciences; Assistant Clinical Professor, Dermatology, Icahn School of Medicine, Mount Sinai, New York City
Dr. Matthew Goldberg has served as Castle Biosciences’ Medical Director since August 2020. Prior to joining Castle, Dr. Goldberg was an Assistant Professor in Dermatology and Pathology at the Icahn School of Medicine at Mount Sinai in New York and retains his affiliation as an Assistant Clinical Professor of Dermatology. Before joining the Mount Sinai Dermatology faculty, he directed Dermatopathology education for the MedStar Georgetown/Washington Hospital Center dermatology residency program. Dr. Goldberg has a background in translational melanoma research and received the Dermatology Foundation Dermatopathology Research Career Development Award for his research in the field of melanoma epigenetics.
Dr. Goldberg graduated summa cum laude from Princeton University and received his medical degree from the Icahn School of Medicine at Mount Sinai, where he graduated with distinction in research. Dr. Goldberg completed his dermatology residency at the University of California, San Francisco, and completed a dermatopathology fellowship at the University of Texas Southwestern. Dr. Goldberg is board certified in dermatology and dermatopathology.
Mike Montalto
Chief Scientific Officer
Mike Montalto, PhD
Chief Scientific Officer, PathAI
Mike Montalto of PathAI has experience developing digital pathology diagnostic products and driving cutting-edge translational research in a large biopharmaceutical setting. Mike joined PathAI in November 2019 to use AI-powered pathology to support the development of new therapies and diagnostics for patients.
Prior to joining PathAI, Mike led the majority of clinical biomarker central laboratories in Translational Medicine at Bristol-Myers Squibb including translational and digital pathology, immunohistochemistry, clinical genomics, clinical flow cytometry, pre-clinical and clinical non-invasive imaging, biorepository and clinical biomarker sample operations in support of all therapeutic areas for global clinical trials, precision medicine, and companion diagnostics development. Prior to BMS, Montalto was a co-founder and executive of Omnyx, LLC, a joint venture of GE Healthcare and the University of Pittsburgh Medical Center that commercialized diagnostic pathology imaging and software products. Prior to this, Montalto was the Molecular Imaging and Diagnostics Advanced Technology Leader at General Electric, where he was a lead inventor of MultiOmyx™, a proprietary pathology-based multiplexing technology for biomarker discovery.
Throughout his career, Mike had a passion for advancing imaging technologies toward unmet scientific and medical needs in a commercial setting to be able to impact patients.
Mike has served as a member of NIH study sections for in vivo molecular imaging centers, designed and led global clinical trials for the registration of digital pathology devices and served as a board member and president of the Digital Pathology Association (DPA). Under his leadership, the DPA successfully collaborated with the FDA to establish industry wide regulatory guidance and clinical trial designs for the clinical use of digital pathology devices. He currently serves on the DPA executive committee as immediate past-president, and on the DPA Foundation’s board of directors. Dr. Montalto earned his PhD in tumor biology from Albany Medical College and received his post-doctoral training in anti-inflammatory drug discovery and whole animal physiology at Brigham and Women’s Hospital, Harvard Medical School.
Anil Parwani, MD, PhD
Professor of Pathology, The Ohio State University; Vice Chair and Director of Anatomical Pathology, The Ohio State University; Director of Pathology Informatics, Director of Digital Pathology Shared Resource, The James Cancer Hospital
Anil Parwani, MD, PhD
Professor of Pathology, The Ohio State University; Vice Chair and Director of Anatomical Pathology, The Ohio State University; Director of Pathology Informatics, Director of Digital Pathology Shared Resource, The James Cancer Hospital
Anil Parwani, MD, FCAP is a Professor of Pathology and Biomedical Informatics at The Ohio State University. He also serves as the Vice Chair of Anatomical Pathology and Director of Division of Pathology Informatics and Digital Pathology. Dr. Parwani has expertise in digital pathology, artificial intelligence and pathology informatics and has led the way in the implementation of these technologies in several key clinical areas. Dr. Parwani also has expertise in the area of Anatomical Pathology Informatics including designing quality assurance tools, bio banking informatics, clinical and research data integration, applications of whole slide imaging, digital imaging, telepathology, image analysis, artificial intelligence and lab automation. Dr. Parwani has authored over 350 peer-reviewed articles in major scientific journals and several books and book chapters. Dr. Parwani is on the editorial board of several informatics and surgical pathology journals and currently serves as an editor-in-chief of diagnostic pathology and a co-editor-in-chief of the journal of pathology informatics. Dr. Parwani has served on many national and international professional societies including USCAP, Digital Pathology Association, ISUP, GUPS, Association of Pathology Informatics, ASCP and CAP.
Joseph Willis, MD
Professor and Vice Chair for Translational Research, Department of Pathology, Case Western Reserve University and University Hospitals Cleveland Medical Center
Joseph Willis, MD
Professor and Vice Chair for Translational Research, Department of Pathology, Case Western Reserve University and University Hospitals Cleveland Medical Center
Joe Willis received his medical degree at University College Cork and subsequently trained in General Surgery in Ireland in the 1980s. After a year as a Surgery Research Fellow at SUNY Buffalo, he completed his Anatomic and Clinical Pathology residency at the University of Rochester, NY and Surgical Pathology Fellowship at the University of Michigan. He is currently Professor and Vice Chair for Translational Research at the Department of Pathology, Case Western Reserve University and University Hospitals Cleveland Medical Center – where he is a practicing surgical pathologist. He previously served as the hospital Laboratory Director and Clinical Pathology Division Chief for 13 years. Dr Willis has a particular interest in gastrointestinal oncology, having been involved in many NIH sponsored projects for over two decades including the Case GI SPORE. His main focus is centered on tissue based research – helping to identify prognostic and predictive markers related to patient outcomes; as well as integrating recent advances in pathology image analytics into translational cancer research and routine clinical care.